Baidu
map

Prostate Cancer P D:新诊断转移性前列腺癌放射治疗的长期结果

2021-04-25 AlexYang MedSci原创

在转移性前列腺癌患者中,局部治疗的作用在不断发展。近期报道的两项大规模随机试验表明,针对前列腺的放疗可提高低转移负荷患者的总生存(OS)。

在转移性前列腺癌患者中,局部治疗的作用在不断发展。近期报道的两项大规模随机试验表明,针对前列腺的放疗可提高低转移负荷患者的总生存(OS)。

最近,有研究人员回顾了他们中心在这种背景下的前列腺放射治疗经验

研究包括了2005年至2015年期间转诊到一个综合癌症中心的新诊断的转移性激素敏感前列腺癌(mHSPC)男性,他们最初接受雄激素阻断疗法。研究队列包括了410名患者,其中128人接受了前列腺RT。随访中位数为61.0个月。在单变量分析中,接受前列腺RT与OS的改善有关(HR 0.59,95%CI 0.45-0.77,p=0.0001)。接受前列腺RT的患者的OS中位数为47.4个月,而未接受前列腺RT的患者为26.3个月。在多变量Cox模型中,接受前列腺RT仍与OS改善有关(HR 0.69,95%CI 0.50-0.94,p=0.02)。另外,在接受前列腺RT治疗的患者中,BED的增加也与OS的改善有关(HR 0.87,每增加10Gy,95%CI 0.76-0.99,p=0.03)。

接受放疗患者的总生存多变量Cox模型(n=128)

最后,研究人员指出,他们的队列代表了迄今为止报道的最大的单中心原发肿瘤定向RT治疗mHSPC的经验。在该人群中,接受前列腺RT与OS的改善有关,OS获益的程度具有临床意义。因此,RT剂量响应梯度的情况也值得进一步研究。

原始出处:

Scott C Morgan, Oliver E Holmes , Julia Craig et al. Long-term outcomes of prostate radiotherapy for newly-diagnosed metastatic prostate cancer. Prostate Cancer P D. Apr 2021

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1791650, encodeId=af0a1e9165028, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Aug 26 01:00:41 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723772, encodeId=43b41e2377210, content=<a href='/topic/show?id=ac899e0343c' target=_blank style='color:#2F92EE;'>#长期结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97034, encryptionId=ac899e0343c, topicName=长期结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee6a33536665, createdName=zhucaizhong7777, createdTime=Wed Aug 11 17:00:41 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915311, encodeId=bfb419153111c, content=<a href='/topic/show?id=e381586e94d' target=_blank style='color:#2F92EE;'>#新诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58679, encryptionId=e381586e94d, topicName=新诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Wed Jun 02 03:00:41 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965279, encodeId=9c2e9652e9e0, content=已经写进指南了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=86a75470976, createdName=ms4000000681655625, createdTime=Thu May 13 18:04:06 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364722, encodeId=15a01364e225c, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386749, encodeId=730a1386e49ef, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395558, encodeId=71df139555863, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93405, encryptionId=7bbf93405a5, topicName=转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602360, encodeId=d35a1602360bd, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041000, encodeId=a679104100026, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 25 03:00:41 CST 2021, time=2021-04-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1791650, encodeId=af0a1e9165028, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Aug 26 01:00:41 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723772, encodeId=43b41e2377210, content=<a href='/topic/show?id=ac899e0343c' target=_blank style='color:#2F92EE;'>#长期结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97034, encryptionId=ac899e0343c, topicName=长期结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee6a33536665, createdName=zhucaizhong7777, createdTime=Wed Aug 11 17:00:41 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915311, encodeId=bfb419153111c, content=<a href='/topic/show?id=e381586e94d' target=_blank style='color:#2F92EE;'>#新诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58679, encryptionId=e381586e94d, topicName=新诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Wed Jun 02 03:00:41 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965279, encodeId=9c2e9652e9e0, content=已经写进指南了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=86a75470976, createdName=ms4000000681655625, createdTime=Thu May 13 18:04:06 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364722, encodeId=15a01364e225c, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386749, encodeId=730a1386e49ef, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395558, encodeId=71df139555863, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93405, encryptionId=7bbf93405a5, topicName=转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602360, encodeId=d35a1602360bd, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041000, encodeId=a679104100026, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 25 03:00:41 CST 2021, time=2021-04-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1791650, encodeId=af0a1e9165028, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Aug 26 01:00:41 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723772, encodeId=43b41e2377210, content=<a href='/topic/show?id=ac899e0343c' target=_blank style='color:#2F92EE;'>#长期结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97034, encryptionId=ac899e0343c, topicName=长期结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee6a33536665, createdName=zhucaizhong7777, createdTime=Wed Aug 11 17:00:41 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915311, encodeId=bfb419153111c, content=<a href='/topic/show?id=e381586e94d' target=_blank style='color:#2F92EE;'>#新诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58679, encryptionId=e381586e94d, topicName=新诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Wed Jun 02 03:00:41 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965279, encodeId=9c2e9652e9e0, content=已经写进指南了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=86a75470976, createdName=ms4000000681655625, createdTime=Thu May 13 18:04:06 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364722, encodeId=15a01364e225c, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386749, encodeId=730a1386e49ef, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395558, encodeId=71df139555863, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93405, encryptionId=7bbf93405a5, topicName=转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602360, encodeId=d35a1602360bd, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041000, encodeId=a679104100026, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 25 03:00:41 CST 2021, time=2021-04-25, status=1, ipAttribution=)]
    2021-06-02 rgjl
  4. [GetPortalCommentsPageByObjectIdResponse(id=1791650, encodeId=af0a1e9165028, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Aug 26 01:00:41 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723772, encodeId=43b41e2377210, content=<a href='/topic/show?id=ac899e0343c' target=_blank style='color:#2F92EE;'>#长期结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97034, encryptionId=ac899e0343c, topicName=长期结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee6a33536665, createdName=zhucaizhong7777, createdTime=Wed Aug 11 17:00:41 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915311, encodeId=bfb419153111c, content=<a href='/topic/show?id=e381586e94d' target=_blank style='color:#2F92EE;'>#新诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58679, encryptionId=e381586e94d, topicName=新诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Wed Jun 02 03:00:41 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965279, encodeId=9c2e9652e9e0, content=已经写进指南了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=86a75470976, createdName=ms4000000681655625, createdTime=Thu May 13 18:04:06 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364722, encodeId=15a01364e225c, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386749, encodeId=730a1386e49ef, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395558, encodeId=71df139555863, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93405, encryptionId=7bbf93405a5, topicName=转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602360, encodeId=d35a1602360bd, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041000, encodeId=a679104100026, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 25 03:00:41 CST 2021, time=2021-04-25, status=1, ipAttribution=)]
    2021-05-13 ms4000000681655625

    已经写进指南了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1791650, encodeId=af0a1e9165028, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Aug 26 01:00:41 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723772, encodeId=43b41e2377210, content=<a href='/topic/show?id=ac899e0343c' target=_blank style='color:#2F92EE;'>#长期结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97034, encryptionId=ac899e0343c, topicName=长期结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee6a33536665, createdName=zhucaizhong7777, createdTime=Wed Aug 11 17:00:41 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915311, encodeId=bfb419153111c, content=<a href='/topic/show?id=e381586e94d' target=_blank style='color:#2F92EE;'>#新诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58679, encryptionId=e381586e94d, topicName=新诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Wed Jun 02 03:00:41 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965279, encodeId=9c2e9652e9e0, content=已经写进指南了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=86a75470976, createdName=ms4000000681655625, createdTime=Thu May 13 18:04:06 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364722, encodeId=15a01364e225c, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386749, encodeId=730a1386e49ef, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395558, encodeId=71df139555863, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93405, encryptionId=7bbf93405a5, topicName=转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602360, encodeId=d35a1602360bd, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041000, encodeId=a679104100026, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 25 03:00:41 CST 2021, time=2021-04-25, status=1, ipAttribution=)]
    2021-04-26 lsndxfj
  6. [GetPortalCommentsPageByObjectIdResponse(id=1791650, encodeId=af0a1e9165028, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Aug 26 01:00:41 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723772, encodeId=43b41e2377210, content=<a href='/topic/show?id=ac899e0343c' target=_blank style='color:#2F92EE;'>#长期结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97034, encryptionId=ac899e0343c, topicName=长期结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee6a33536665, createdName=zhucaizhong7777, createdTime=Wed Aug 11 17:00:41 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915311, encodeId=bfb419153111c, content=<a href='/topic/show?id=e381586e94d' target=_blank style='color:#2F92EE;'>#新诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58679, encryptionId=e381586e94d, topicName=新诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Wed Jun 02 03:00:41 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965279, encodeId=9c2e9652e9e0, content=已经写进指南了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=86a75470976, createdName=ms4000000681655625, createdTime=Thu May 13 18:04:06 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364722, encodeId=15a01364e225c, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386749, encodeId=730a1386e49ef, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395558, encodeId=71df139555863, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93405, encryptionId=7bbf93405a5, topicName=转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602360, encodeId=d35a1602360bd, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041000, encodeId=a679104100026, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 25 03:00:41 CST 2021, time=2021-04-25, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1791650, encodeId=af0a1e9165028, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Aug 26 01:00:41 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723772, encodeId=43b41e2377210, content=<a href='/topic/show?id=ac899e0343c' target=_blank style='color:#2F92EE;'>#长期结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97034, encryptionId=ac899e0343c, topicName=长期结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee6a33536665, createdName=zhucaizhong7777, createdTime=Wed Aug 11 17:00:41 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915311, encodeId=bfb419153111c, content=<a href='/topic/show?id=e381586e94d' target=_blank style='color:#2F92EE;'>#新诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58679, encryptionId=e381586e94d, topicName=新诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Wed Jun 02 03:00:41 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965279, encodeId=9c2e9652e9e0, content=已经写进指南了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=86a75470976, createdName=ms4000000681655625, createdTime=Thu May 13 18:04:06 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364722, encodeId=15a01364e225c, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386749, encodeId=730a1386e49ef, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395558, encodeId=71df139555863, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93405, encryptionId=7bbf93405a5, topicName=转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602360, encodeId=d35a1602360bd, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041000, encodeId=a679104100026, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 25 03:00:41 CST 2021, time=2021-04-25, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1791650, encodeId=af0a1e9165028, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Aug 26 01:00:41 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723772, encodeId=43b41e2377210, content=<a href='/topic/show?id=ac899e0343c' target=_blank style='color:#2F92EE;'>#长期结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97034, encryptionId=ac899e0343c, topicName=长期结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee6a33536665, createdName=zhucaizhong7777, createdTime=Wed Aug 11 17:00:41 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915311, encodeId=bfb419153111c, content=<a href='/topic/show?id=e381586e94d' target=_blank style='color:#2F92EE;'>#新诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58679, encryptionId=e381586e94d, topicName=新诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Wed Jun 02 03:00:41 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965279, encodeId=9c2e9652e9e0, content=已经写进指南了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=86a75470976, createdName=ms4000000681655625, createdTime=Thu May 13 18:04:06 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364722, encodeId=15a01364e225c, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386749, encodeId=730a1386e49ef, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395558, encodeId=71df139555863, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93405, encryptionId=7bbf93405a5, topicName=转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602360, encodeId=d35a1602360bd, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041000, encodeId=a679104100026, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 25 03:00:41 CST 2021, time=2021-04-25, status=1, ipAttribution=)]
    2021-04-26 sunylz
  9. [GetPortalCommentsPageByObjectIdResponse(id=1791650, encodeId=af0a1e9165028, content=<a href='/topic/show?id=b77f14e4541' target=_blank style='color:#2F92EE;'>#Prostate Ca#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14745, encryptionId=b77f14e4541, topicName=Prostate Ca)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Thu Aug 26 01:00:41 CST 2021, time=2021-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723772, encodeId=43b41e2377210, content=<a href='/topic/show?id=ac899e0343c' target=_blank style='color:#2F92EE;'>#长期结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97034, encryptionId=ac899e0343c, topicName=长期结果)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee6a33536665, createdName=zhucaizhong7777, createdTime=Wed Aug 11 17:00:41 CST 2021, time=2021-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915311, encodeId=bfb419153111c, content=<a href='/topic/show?id=e381586e94d' target=_blank style='color:#2F92EE;'>#新诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58679, encryptionId=e381586e94d, topicName=新诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8b48400, createdName=rgjl, createdTime=Wed Jun 02 03:00:41 CST 2021, time=2021-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965279, encodeId=9c2e9652e9e0, content=已经写进指南了, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=86a75470976, createdName=ms4000000681655625, createdTime=Thu May 13 18:04:06 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364722, encodeId=15a01364e225c, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386749, encodeId=730a1386e49ef, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1395558, encodeId=71df139555863, content=<a href='/topic/show?id=7bbf93405a5' target=_blank style='color:#2F92EE;'>#转移性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93405, encryptionId=7bbf93405a5, topicName=转移性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/656F31B644588474D1C46903A7F84373/100, createdBy=4e842500199, createdName=ms24272190615788285182, createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602360, encodeId=d35a1602360bd, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Apr 26 15:00:41 CST 2021, time=2021-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041000, encodeId=a679104100026, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 25 03:00:41 CST 2021, time=2021-04-25, status=1, ipAttribution=)]
    2021-04-25 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

BJU Int:游离/总前列腺特异性抗原(PSA)检测与前列腺癌死亡率之间的关联研究

最近,有研究人员探讨了基线前列腺特异性抗原(PSA)(包括游离/总PSA比值)与前列腺癌死亡长期(30年)风险之间是否存在长期关联。

JCO:基因检测对低风险前列腺癌治疗策略选择的影响

风险相对较低的前列腺癌(PCa)患者在立即治疗或主动监测(AS)+延期治疗之间往往面临艰难的选择,基因检测有助于治疗方案选择吗?

Eur Radiol:CTA对前列腺动脉栓塞术的价值

前列腺动脉栓塞术是一个技术上相对困难的手术。然而到目前为止,对影响PAE技术困难度因素的研究十分有限,且迄今为止大多数的相关研究均对患者变量使用主观测量。

Prostate:抑制STAT3可防止体内前列腺癌的骨转移

前列腺癌(PC)转移到骨骼会形成以硬化为主的病变,目前对骨转移性疾病还没有治愈的办法。转录因子信号转导和转录激活因子3(STAT3)认为是转移的驱动因素,但它作为骨转移的治疗靶点的潜力还没有研究。

Br J Cancer:尿液中雌激素水平可作为前列腺癌发生发展的风险指标

前列腺癌(PCa)作为全球男性中第二常见的癌症,在2018年有120万以上的确诊病例,死亡人数超过350,000。

Prostate Cancer P D:恩杂鲁胺或阿比特龙治疗转移去势抵抗性前列腺癌男性的生活质量

恩杂鲁胺与醋酸阿比特龙加泼尼松(AAP)对转移去势抵抗性前列腺癌(mCRPC)的疗效相似,但作用机制不同。

Baidu
map
Baidu
map
Baidu
map